HONG KONG, Sept. 10, 2019 /PRNewswire/ -- Insilico Medicine, a pioneer in next-generation artificial intelligence technology for drug discovery, recently completes a $37 million funding round led by Qiming Venture Partners, joined by Eight Roads, F-Prime Capital, Lilly Asia Ventures, Sinovation Ventures, Baidu Ventures, Pavilion Capital, BOLD Capital Partners and other investors including series A investors.
The Series B funding will be used to commercialize the validated generative chemistry and target identification technology. The company will also build up a senior management team with the experience in the pharmaceutical industry, further develop its pipeline in cancer, fibrosis, NASH, immunology and CNS for the purposes of partnering with the pharmaceutical companies on specific therapeutic programs.
Insilico Medicine has developed and validated a comprehensive drug discovery pipeline which includes a state-of-the-art molecular generator utilizing multiple proprietary generative and reinforcement learning technologies. The company identified promising targets in a variety of therapeutic modalities including cancer, fibrosis, NASH, immunology and CNS. Through a network of joint ventures, partnerships with early-stage biotechnology and large pharmaceutical companies, Insilico Medicine is powering the new digital-age biopharmaceutical industry.
"We are excited to lead the current round of financing in Insilico Medicine," says Nisa Leung, Managing Partner of Qiming Venture Partners. "The company is an industry leader in the AI-powered drug discovery vertical. We look forward to seeing it shortening the time for drug discovery and creating synergies with our portfolio companies."
The company is powering a network of biotechnology, pharmaceutical companies and academic institutions. Since inception the company published or co-published over 70 papers in peer-reviewed journals and artificial intelligence conferences. In its latest research paper published in Nature Biotechnology Insilico demonstrated animal validation of novel molecules generated using the deep generative tensorial reinforcement learning models in human cells and in animals.
For further information, images or interviews, please contact: sherry.zhang@qimingvc.com
About Qiming Venture Partners
Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Shenzhen, Hong Kong, Seattle, Boston and San Francisco Bay Area. Currently, Qiming Venture Partners manages seven US Dollar funds and five RMB funds with over US$4 billion assets under management.
Qiming Venture Partners strives to be the investor of choice for top entrepreneurs in China. Since its debut, the firm has backed over 310 fast-growing and innovative companies across China in the TMT, healthcare sectors. Over 60 companies are already listed on NYSE, NASDAQ, Shanghai Stock Exchange, Shenzhen Stock Exchange, HKEx and Gretai Securities Market or achieved exit through M&A. There are about 30 portfolio companies that have been recognized as unicorns in the industry.
About Insilico Medicine
Insilico Medicine is an artificial intelligence company headquartered in Hong Kong, with R&D and management resources in six countries sourced through hackathons and competitions. The company and its scientists are dedicated to transforming the pharmaceutical industry by developing and applying the next-generation deep learning approaches to every step of the drug discovery and drug development process. The company is constantly collaborating with the most innovative biopharmaceutical companies with disease-relevant assays to validate its solutions and generate high-quality machine-learnable data.
Since 2015 Insilico Medicine is developing a broad range of generative adversarial networks (GANs) and reinforcement learning approaches to identify novel protein targets, generate novel molecular structures with specified properties and generate synthetic data.
Website: http://insilico.com/
